Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
40,65 USD | -4,87% | -1,07% | -11,75% |
Attività
Numero di dipendenti: 255
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 48 | 21/10/13 |
Simon Pimstone
FOU | Founder | 56 | 05/11/96 |
Sherry Aulin
DFI | Director of Finance/CFO | 40 | 01/01/11 |
Chief Tech/Sci/R&D Officer | - | 23/08/21 | |
Sheila M. Grant
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/20 |
Jodi Regts
IRO | Public Communications Contact | - | 01/12/15 |
Corporate Officer/Principal | - | 17/08/20 | |
Andrea DiFabio
LAW | General Counsel | 55 | 07/11/22 |
James Empfield
PRN | Corporate Officer/Principal | - | 01/02/16 |
Corporate Officer/Principal | 63 | 01/03/01 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 05/11/20 |
Mohammad Azab
BRD | Director/Board Member | 68 | 01/10/03 |
Justin Gover
BRD | Director/Board Member | 53 | 08/08/23 |
Gary Patou
BRD | Director/Board Member | 65 | 01/01/04 |
Simon Pimstone
FOU | Founder | 56 | 05/11/96 |
Steven Gannon
BRD | Director/Board Member | 62 | 21/05/15 |
Ian Mortimer
CEO | Chief Executive Officer | 48 | 21/10/13 |
Dawn Svoronos
BRD | Director/Board Member | 70 | 27/09/16 |
Director/Board Member | 66 | 03/06/21 | |
Gillian Cannon
BRD | Director/Board Member | 60 | 08/08/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 75 463 489 | 74 078 341 ( 98,16 %) | 0 | 98,16 % |
Coordinate società
Xenon Pharmaceuticals, Inc.
3650 Gilmore Way Suite 200
V5G 4W8, Burnaby
+604 484 3300
http://www.xenon-pharma.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-11,75% | 3,07 Mrd | |
-3,46% | 102 Mrd | |
+1,41% | 96,09 Mrd | |
+2,13% | 22,28 Mrd | |
-15,84% | 21,4 Mrd | |
-9,21% | 18,14 Mrd | |
-39,98% | 17,02 Mrd | |
-14,65% | 16,09 Mrd | |
+4,39% | 13,83 Mrd | |
+31,35% | 11,97 Mrd |
- Borsa valori
- Azioni
- Azione XENE
- Società Xenon Pharmaceuticals Inc.